Conferences & Events

Found 86,611 articles

• 

  Cell and Gene Therapies Shatter Prior Records, with Continued Growth Expected

  1/15/2021

  Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), painted a rosy picture despite a few challenges at the 2021 Cell & Gene State of the Industry Briefing during this year’s Biotech Showcase, held virtually January 11-15.

• Cipher Pharmaceuticals Receives Arbitration Award on Trulance

  1/15/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland ("Bausch Health") relating to the License, Development and Commercialization Agreement (the "Agreement") of Trulance®

• Amyris Ranked Among World's Top Social And Environmental Impact Companies By Real Leaders®️

  1/15/2021

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced it has been selected as one of the top global organizations making a positive social or environmental impact.

• Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

  1/15/2021

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).

• AlloSource's ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting

  1/15/2021

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced its ProChondrix® CR allograft, will be featured in a presentation by Dr. David Argo at the British Patellofemoral Society Meeting, January 18-19, 2021.

• BioSig to Present at the 26th Annual International AF SymposiumPURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute

  1/15/2021

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be presenting at the 26th Annual International Atrial Fibrillation  Symposium, held virtually on January 29-31, 2021.

• BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting

  1/15/2021

  BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will present three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at the 2021 North American Neuromodulation Society Meeting (NANS) taking place virtually January 15-16, 2021.

• ViewRay Announces Participation in the B. Riley Oncology Investor Conference

  1/15/2021

  ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investor Conference on Wednesday, January 20, 2021.

• Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

  1/15/2021

  Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021.

• Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

  1/15/2021

  Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced the presentation of data from its Phase 1b/2 study in KRAS-mutated metastatic colorectal cancer (mCRC) as part of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

• Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital

  1/15/2021

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.

• Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and WebcastCall scheduled for Tuesday, February 9th at 4:30 pm Eastern Time

  1/15/2021

  Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its third fiscal quarter ended December 31, 2020 on Tuesday, Februa

• Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement

  1/15/2021

   Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Easter

• Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference

  1/15/2021

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D’Silva of B. Riley Securities on Wednesday, January 20, 2021 at 10:30 am ET.

• Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast

  1/15/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today provided the replay link for the Companys January 14, 2021 investor webcast and a recap of the key points from the presentation.

• Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

  1/15/2021

  Isofol Medical AB (publ) ("Isofol"), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene exp

• TG Therapeutics to Participate in the B. Riley Securities Oncology Investor ConferenceFireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET

  1/15/2021

  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Oncology Investor Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 10:00 AM ET. A live webcast of this presentation will be available on the Events page, located within the Investors

• AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ETAIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones

  1/15/2021

  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the recently announced commencement of the treatment of subjects with COVID-19-induced chronic fatigue-like symptoms in the amended AMP-511 trial, recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions

• AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements

  1/14/2021

  AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39th Annual J.P. Morgan Healthcare Conference.

• Cureduchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollout

  1/14/2021

  CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne community needs.